(SANA) Sana Biotechnology - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 746m USD | Total Return: 2.6% in 12m
Avg Turnover: 10.9M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 16.5% YoY
Interest Coverage Ratio -3.8 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Sana Biotechnology, Inc. is a clinical-stage biotechnology firm specializing in engineered cell therapies. The company utilizes ex vivo and in vivo platforms to develop treatments for type 1 diabetes, B-cell mediated autoimmune diseases, and various oncology indications. Its primary focus involves hypoimmune (HIP) modifications designed to prevent immune system rejection of transplanted cells.
The company operates within the cell and gene therapy sector, a capital-intensive industry characterized by high research and development costs and rigorous multi-phase clinical trial requirements. Sana’s business model relies on strategic intellectual property licensing, including CRISPR Cas12b technology from Beam Therapeutics and collaborations with institutions like Harvard University and the Mayo Clinic.
Current pipeline assets include UP421, an allogeneic islet cell product in Phase 1 trials, and several preclinical candidates targeting hematologic malignancies. Examining the companys valuation metrics on ValueRay can provide deeper insight into its current financial standing relative to sector peers. Headquartered in Seattle, the firm transitioned from FD Therapeutics to its current identity in 2018.
- Clinical trial data readouts for hypoimmune-modified cell therapies drive investor sentiment
- Cash runway and capital expenditure requirements impact long-term operational sustainability
- Regulatory approval hurdles for CRISPR Cas12b gene editing technology influence pipeline progress
- Strategic partnerships with Beam Therapeutics and Mayo Clinic validate platform technology value
- Expansion into B cell mediated autoimmune disease markets diversifies future revenue potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 14.49 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.35 > 3% & CFO -132.6m > Net Income -242.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (276.9m) vs 12m ago 16.53% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 3.43%; Δ -3.43% > 0%) |
| Interest Coverage Ratio: -3.80 > 6 (EBIT TTM -191.6m / Interest Expense TTM 50.4m) |
| A: 0.07 (Total Current Assets 111.7m - Total Current Liabilities 86.3m) / Total Assets 373.6m |
| B: -5.08 (Retained Earnings -1.90b / Total Assets 373.6m) |
| C: -0.47 (EBIT TTM -191.6m / Avg Total Assets 409.5m) |
| D: 0.47 (Book Value of Equity 119.2m / Total Liabilities 254.4m) |
| Altman-Z'' = -18.75 = D |
As of June 12, 2026, the stock is trading at USD 2.77 with a total of 2,949,611 shares traded.
Over the past week, the price has changed by -6.42%,
over one month by -22.19%,
over three months by -12.06% and
over the past year by +2.59%.
Sana Biotechnology has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SANA.
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.6 | 209.4% |
P/B = 6.9083
Revenue TTM = 0.0 USD
EBIT TTM = -191.6m USD
EBITDA TTM = -180.1m USD
Long Term Debt = 60.5m USD (estimated: total debt 75.3m - short term 14.9m)
Short Term Debt = 14.9m USD (from shortTermDebt, last quarter)
Debt = 75.3m USD (from shortLongTermDebtTotal, last quarter) (leases 75.3m already included)
Net Debt = -25.8m USD (calculated: Debt 75.3m - CCE 101.1m)
Enterprise Value = 720.0m USD (745.8m + Debt 75.3m - CCE 101.1m)
Interest Coverage Ratio = -3.80 (Ebit TTM -191.6m / Interest Expense TTM 50.4m)
EV/FCF = -5.39x (Enterprise Value 720.0m / FCF TTM -133.6m)
FCF Yield = -18.56% (FCF TTM -133.6m / Enterprise Value 720.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 12.8m) / Revenue TTM)
Tobins Q-Ratio = 1.93 (Enterprise Value 720.0m / Total Assets 373.6m)
Interest Expense / Debt = 66.91% (Interest Expense 50.4m / Debt 75.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -151.4m (EBIT -191.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.29 (Total Current Assets 111.7m / Total Current Liabilities 86.3m)
Debt / Equity = 0.63 (Debt 75.3m / totalStockholderEquity, last quarter 119.2m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -25.8m / EBITDA -180.1m)
Debt / FCF = 0.19 (negative FCF - burning cash) (Net Debt -25.8m / FCF TTM -133.6m)
Total Stockholder Equity = 149.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.09% (Net Income -242.0m / Total Assets 373.6m)
RoE = -161.9% (Net Income TTM -242.0m / Total Stockholder Equity 149.5m)
RoCE = -91.25% (EBIT -191.6m / Capital Employed (Equity 149.5m + L.T.Debt 60.5m))
RoIC = -50.08% (negative operating profit) (NOPAT -151.4m / Invested Capital 302.2m)
WACC = 11.15% (E(745.8m)/V(821.1m) * Re(12.28%) + (debt cost/tax rate unavailable))
Discount Rate = 12.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 16.24%
[DCF] Fair Price = unknown (Cash Flow -133.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.58 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=+18.20% | Revisions=-14% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+17.80% | Revisions=-14% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.60 | Chg30d=-2.58% | Revisions=-33% | GrowthEPS=+11.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.54 | Chg30d=-1.41% | Revisions=+33% | GrowthEPS=+9.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -33%